Company intelligence / Profile preview
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Shanghai Yidian Pharmaceutical Technology Development is a private Chinese biotech company focused on the development of small molecule therapeutics for oncology and other indications. Its lead program HTMC‑0435 is a PARP inhibitor currently in Phase 2 clinical trials for advanced malignant solid neoplasms and biliary tract cancer. The company has several programs at IND/Phase 1 stages targeting various cancers and related indications. No approved products as of May 2025.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesChemical drugs
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Beyond the preview
Go deeper on Shanghai Yidian Pharmaceutical Technology Development Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Yidian Pharmaceutical Technology Development Co., Ltd..